Preparing Site-Specific Antibody-Drug Conjugates (ADC) Through Noncanonical Amino Acid Mutagenesis

Authors: Joshi, Manas; Pham, Quan; Sarkar, Rahul; Chatterjee, Abhishek

Source journal: Methods in molecular biology (Clifton, N.J.) (2027-01-01)

DOI: 10.1007/978-1-0716-5719-5_14

Abstract

Antibody-drug conjugates (ADCs) are targeted biopharmaceuticals, enabling precise delivery of cytotoxic small-molecule drugs to target cells using monoclonal antibodies. Traditional methods for preparing ADCs that leverage native amino acid residues often lack control over the site and stoichiometry of drug attachment, resulting in product heterogeneity and unfavorable pharmacological properties. These challenges can be mitigated using the genetic code expansion (GCE) technology, which enables incorporation of bioorthogonal noncanonical amino acids (ncAAs) into virtually any predefined site within an antibody. This approach enables preparation of homogeneous ADCs with precise control over the site and drug-to-antibody ratio (DAR). In this chapter, we describe a method for recombinantly expressing and purifying a full-length antibody containing an azide-ncAA, labeling it with a cytotoxic drug molecule using a bioorthogonal strain-promoted azide-alkyne cycloaddition reaction to generate a homogeneous ADC, followed by analytical characterization and assessment of its selective cytotoxicity toward cells expressing the target receptor.

Read the full text

Related topics

Related open access articles

Abstract and bibliographic data from PubMed (U.S. National Library of Medicine). Copyright of the abstract belongs to the original publisher or authors.